CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 97 filers reported holding CABALETTA BIO INC in Q3 2023. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,148,851 | +552.8% | 141,186 | +453.7% | 0.00% | – |
Q2 2023 | $329,179 | +349.7% | 25,498 | +188.1% | 0.00% | – |
Q1 2023 | $73,197 | +546.0% | 8,851 | +622.5% | 0.00% | – |
Q4 2022 | $11,331 | +88.8% | 1,225 | -86.7% | 0.00% | – |
Q3 2022 | $6,000 | -62.5% | 9,194 | -39.7% | 0.00% | – |
Q2 2022 | $16,000 | -75.8% | 15,247 | -52.9% | 0.00% | – |
Q1 2022 | $66,000 | +144.4% | 32,379 | +355.3% | 0.00% | – |
Q4 2021 | $27,000 | -84.7% | 7,111 | -51.0% | 0.00% | – |
Q3 2021 | $176,000 | +1.1% | 14,507 | -28.2% | 0.00% | – |
Q2 2021 | $174,000 | +56.8% | 20,205 | +102.5% | 0.00% | – |
Q1 2021 | $111,000 | +177.5% | 9,978 | +214.8% | 0.00% | – |
Q4 2020 | $40,000 | -9.1% | 3,170 | -22.0% | 0.00% | – |
Q3 2020 | $44,000 | -41.3% | 4,065 | -39.0% | 0.00% | – |
Q2 2020 | $75,000 | +200.0% | 6,659 | +99.3% | 0.00% | – |
Q1 2020 | $25,000 | +56.2% | 3,342 | +194.4% | 0.00% | – |
Q4 2019 | $16,000 | – | 1,135 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |